Clarivate Plc - CLVT STOCK NEWS

Clarivate (NYSE:CLVT) has released its twelfth annual Drugs to Watch™ report, identifying 11 potential blockbuster therapies expected to achieve significant market success or transform treatment paradigms by 2030. The report highlights innovations in obesity, oncology, and gene therapy, powered by Clarivate's Cortellis intelligence suite.

Key featured drugs include AWIQLI® (first weekly insulin), CagriSema (obesity treatment), COBENFY™ (schizophrenia therapy), and EBGLYSS™ (atopic dermatitis treatment). The report also analyzes the chronic disease market in Mainland China and explores industry trends including AI integration, radiopharmaceutical theranostics, and the growing importance of real-world data in healthcare decisions.

The analysis demonstrates Clarivate's strong track record, with 12 out of 13 molecules identified in last year's report already approved and launched.

Clarivate (NYSE:CLVT) has announced a new $500 million share repurchase program for its outstanding ordinary shares, effective from January 1, 2025, through December 31, 2026. This program replaces the current one ending December 31, 2024, under which the company repurchased $300 million of shares, including $200 million in Q3-Q4 2024.

Additionally, Clarivate has prepaid $75 million of term-loan debt in Q4, bringing total 2024 prepayments to $133 million. The new buyback program, part of the company's Value Creation Plan, allows for open-market purchases through various methods, including Rule 10b5-1 trading plans, subject to market conditions and regulatory requirements.

Clarivate (NYSE: CLVT) has launched AI Search in Derwent™, an AI-powered patent search solution. The tool integrates AI with the Derwent World Patents Index (DWPI)™ to enhance innovation decision-making by delivering faster and more relevant patent search results. The AI Search leverages a language transformer model to understand context and retrieve pertinent results from over 160 million patent records. This solution aids patent researchers, attorneys, and IP professionals in conducting accurate first-pass patentability searches and validating results to ensure no relevant records are missed. DWPI, covering more than 120 million patents and over 62 million invention families, underpins the AI Search with manually written abstracts summarizing each invention's novelty and advantage. Gordon Samson, President of Intellectual Property at Clarivate, highlighted that this technology reduces the number of patents professionals need to review, thus speeding up and improving decision-making.

Clarivate and the Chinese Academy of Sciences have released their 11th annual Research Fronts 2024 report, identifying 125 dynamic research specialties in sciences and social sciences. The report highlights 110 'hot' and 15 'emerging' research fronts, including studies on monoclonal antibodies for early Alzheimer's treatment and Generative AI in education.

The analysis, based on Clarivate's Essential Science Indicators database, tracks patterns of co-citation among scientific papers. The accompanying comparative analysis shows the United States leading research activities across 11 areas, followed by Mainland China, with the UK, Germany, and France completing the top five countries.

Clarivate Plc (NYSE: CLVT) announced that Daikin Industries has selected IPfolio™ to optimize its intellectual property assets management. The leading air conditioner manufacturer will use this cloud-based solution to enhance operational efficiency, manage increasing IP filing volumes, and eliminate manual processes. IPfolio will be implemented across Daikin's global offices to facilitate collaboration through connected services and integrations. The solution's configurability will help Daikin meet its unique IP asset management needs while enabling more confident strategic decision-making and sustainable growth.

BioWorld, published by Clarivate (NYSE:CLVT), has launched 'Healing the Health Divide,' a seven-part series examining disparities in women's health research and funding. The series reveals that only 15% of venture capital funding in 2023 went to women's health-focused biopharma companies, while just 8% of funded companies included women's health assets. Key findings show that women's health deals since 2019 represent only 18.5% of all analyzed deals from 473 companies.

The series explores gender bias in research, untapped market potential, and efforts to improve diagnosis and treatment of conditions like endometriosis and cardiovascular disease, which disproportionately affect women.

Clarivate has unveiled its 2024 Highly Cited Researchers list, recognizing 6,636 influential researchers from over 1,200 institutions across 59 nations. The analysis reveals significant shifts in global research influence, with Mainland China and Hong Kong SAR gaining prominence while the U.S. share gradually decreases. The U.S. maintains leadership with 2,507 researchers (36.4%), while China follows with 1,405 researchers (20.4%). The Chinese Academy of Sciences leads institutions with 308 recognitions. The selection process has been enhanced with new filters to address publication manipulation and ensure research integrity.

Clarivate (NYSE:CLVT) and Healthcare Executive have released a report titled 'A Decade of Innovation, A Decade to Come,' analyzing Mainland China's transformation into a global biopharma powerhouse. The report highlights China's advancement to become one of the top three countries for initial drug launches, with its R&D expenditure growing 3.5 times over the past decade. Key developments include regulatory reforms, increased investment, and improved patient access to therapies. The National Reimbursement Drug List negotiations have reduced drug costs by 50-60%, while China's share of global licensing deals has increased from 6.5% to nearly 9% since 2015.

Clarivate (NYSE:CLVT) has announced the winners of its 2023 Healthcare Business Insights Revenue Cycle Awards, marking the program's 12th year. The awards recognize U.S. healthcare organizations for outstanding revenue cycle key performance indicators (KPIs), based on fiscal year data.

This year's recipients include Roper St. Francis Healthcare (Physician Group) from South Carolina, Bon Secours Mercy Health (Physician Group) from Ohio, Bronson Methodist Hospital from Michigan, and Roper St. Francis Healthcare from South Carolina. Winners demonstrated top decile performance across various financial metrics.